$CLSN News Article - Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
https://marketwirenews.com/news-releases/cels...09541.html